Silexion Therapeutics enters collaboration with Catalent

Written by Emily J. Thompson, Senior Investment Analyst

CTLT%

SLXN-6.97%

Updated: Apr 23 2025

0mins

Collaboration Announcement: Silexion Therapeutics has partnered with Catalent for the formulation development and clinical manufacturing of its siRNA candidate, SIL204, focusing on optimizing delivery methods for KRAS-driven cancers.
Development Timeline: The collaboration aims to advance SIL204 through preclinical studies and into clinical trials, with regulatory submissions planned for 2025 and 2026 in Israel and the European Union.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Silexion Therapeutics enters collaboration with Catalent

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Amazon's AI Growth Fuels Stock Rise, Nasdaq Predicted to Soar by 2026

Peter Thiel Sells Nvidia, Invests in Apple and Microsoft

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch